

Amendments to the Claims:

This listing of claims will replace all previous versions and listings of claims in the application:

1-27. (canceled)

28. (currently amended) An isolated polypeptide comprising an amino acid sequence having at least 80% ~~amino acid~~ sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:194;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;

wherein the polypeptide stimulates the uptake of glucose or FFA (free fatty acid) by adipocyte cells.

29. (currently amended) The isolated polypeptide of Claim 28 comprising an amino acid sequence having at least 85% ~~amino acid~~ sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:194;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;

wherein the polypeptide stimulates the uptake of glucose or FFA (free fatty acid) by adipocyte cells.

30. (currently amended) The isolated polypeptide of Claim 28 comprising an amino acid sequence having at least 90% ~~amino acid~~ sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:194;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;

wherein the polypeptide stimulates the uptake of glucose or FFA (free fatty acid) by adipocyte cells.

31. (currently amended) The isolated polypeptide of Claim 28 comprising an amino acid sequence having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:194;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;

wherein the polypeptide stimulates the uptake of glucose or FFA (free fatty acid) by adipocyte cells.

32. (currently amended) The isolated polypeptide of Claim 28 comprising an amino acid sequence having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:194;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;

wherein the polypeptide stimulates the uptake of glucose or FFA (free fatty acid) by adipocyte cells.

33. (previously presented) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:194;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232.

34. (previously presented) The isolated polypeptide of Claim 33 comprising the amino acid sequence of the polypeptide of SEQ ID NO:194.

35. (previously presented) The isolated polypeptide of Claim 33 comprising the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide.

36. (canceled)

37. (canceled)

38. (previously presented) The isolated polypeptide of Claim 33 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232.

39. (previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 28 fused to a heterologous polypeptide.

40. (previously presented) The chimeric polypeptide of Claim 39, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

41. (new) An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:194;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;

wherein the nucleic acid encoding the polypeptide is amplified in lung and colon tumors.

42. (new) An isolated polypeptide of Claim 41 comprising an amino acid sequence having at least 85% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:194;

(b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;
wherein the nucleic acid encoding the polypeptide is amplified in lung and colon tumors.

43. (new) An isolated polypeptide of Claim 41 comprising an amino acid sequence having at least 90% sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:194;

(b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;
wherein the nucleic acid encoding the polypeptide is amplified in lung and colon tumors.

44. (new) An isolated polypeptide of Claim 41 comprising an amino acid sequence having at least 95% sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:194;

(b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;
wherein the nucleic acid encoding the polypeptide is amplified in lung and colon tumors.

45. (new) An isolated polypeptide of Claim 41 comprising an amino acid sequence having at least 99% sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:194;

(b) the amino acid sequence of the polypeptide of SEQ ID NO:194, lacking its associated signal peptide;

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203232;

wherein the nucleic acid encoding the polypeptide is amplified in lung and colon tumors.

46. (new) A chimeric polypeptide comprising a polypeptide according to Claim 41 fused to a heterologous polypeptide.

47. (new) The chimeric polypeptide of Claim 46, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.